FDA says its new Adverse Event Monitoring System, or AEMS, is designed as a centralized platform not just for adverse event reports, but also for consumer complaints, regulatory misconduct reports, and whistleblower submissions across FDA centers. The agency says this broader setup is intended to improve trend identification, data quality, consistency, analytics, and cross-product surveillance.
That matters for digital pharmacovigilance because safety intelligence does not always begin as a clean ICSR. Sometimes it emerges through product complaints, quality-linked issues, or unusual reporting patterns that only become meaningful when multiple information streams are considered together. AEMS suggests FDA is building toward a more connected surveillance model.
For industry teams, the takeaway is bigger than the public dashboard itself. The real signal is that digital PV maturity increasingly depends on integration, not just automation. That conclusion is an inference from how FDA describes AEMS
0 Comments